NASDAQ · Biotechnology

Gossamer Bio, Inc. (GOSS) Stock

$0.19 +38.24% NASDAQ: GOSS Healthcare

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Valuation

MetricValue
Price$0.19
Market Cap$44.10M
P/E Ratio-0.17
P/B Ratio-0.20
P/S Ratio0.57
EPS (TTM)$-0.75
52-Week High$3.87
52-Week Low$0.11
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE174.85%
ROA-139.95%
ROCE-246.96%
Gross Margin-341.67%
Operating Margin-339.58%
Net Margin-324.82%
Debt/Equity-1.26
Current Ratio2.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$115.0M$48.0M
Operating Profit$-216.0M$-219.0M$-184.0M$-60.0M$-163.0M
Net Profit$-234.0M$-229.0M$-180.0M$-57.0M$-170.0M
EPS$-3.33$-2.84$-1.18$-0.25$-0.75
Op Margin———-52.2%-336.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$344.0M$272.0M$312.0M$315.0M$172.0M
Total Liabilities$222.0M$260.0M$249.0M$286.0M$295.0M
Cash$183.0M$112.0M$32.0M$46.0M$38.0M
Borrowings$185.0M$226.0M$212.0M$203.0M$203.0M

Latest News

Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes Simply Wall St. · Jul 2, 2026 Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants Business Wire · Jul 1, 2026 Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk Simply Wall St. · Jun 18, 2026 Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ... GuruFocus.com · Jun 17, 2026 Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Business Wire · Jun 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-189.0M$-187.0M$-159.0M$-3.0M$-171.0M
Investing Cash Flow$-119.0M$-2.0M$-111.0M$29.0M$156.0M
Financing Cash Flow$3.0M$3.0M$0$1.0M$0
Net Cash Flow$-303.0M$-71.0M$-80.0M$14.0M$-8.0M
Free Cash Flow$-191.0M$-188.0M$-159.0M$-3.0M$-171.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.30
FCF Yield-387.79%
Quick Ratio2.67
Interest Coverage-14.82
Return 1Y-89.31%
Return 3Y-89.60%
Return 5Y-97.88%

Ownership

Insiders Held1.52%
Institutions Held73.64%
Institutions Float Held74.78%
Institutional HolderSharesReport Date
Blackrock Inc.16,826,6952026-03-31
Kalehua Capital Management LLC10,236,2932026-03-31
AQR Capital Management, LLC10,126,8972026-03-31
Vanguard Capital Management LLC9,394,5932026-03-31
Arch Venture Management, Llc8,055,9162026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%
LXRX $2.47 +4.66% -15.93 $1.10B 0.00%
OLMA $11.28 -1.48% -3.96 $985.28M 0.00%

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio, Inc. is led by CEO Faheem Hasnain, employs 144 people, headquartered in US, publicly traded since 2019.

Gossamer Bio, Inc. (GOSS) stock trades at $0.19 with a market capitalization of $44.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.17, price-to-book of -0.20, price-to-sales of 0.57. Over the past 52 weeks the stock has ranged between $0.11 and $3.87, and currently trades 95.1% below its 52-week high.

On profitability, Gossamer Bio, Inc. generates a return on equity (ROE) of 174.85% — well above the market average, a sign of a high-quality business, return on capital employed of -246.96%, an operating margin of -339.58%, a net profit margin of -324.82%.

Official website: www.gossamerbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides